Annual Report 2003 Aventis - Sanofi

More documents

Recommendations

Info

Expert Opinion on Infectious Diseases What is the current status in the treatment and control of bacterial infections? The three most common respiratory infections – sinusitis, pneumonia and middleear infections – account for 75 % of all outpatient antibiotic prescriptions. But the trouble with bugs is that it’s very hard to know where they will land. Diseases can explode out of nowhere, occurring both inside and outside of hospitals. So far, we’ve more or less been able to keep up with infectious diseases. However, bacteria constantly develop resistance to antibiotics and it’s impossible to predict when resistance will occur. So our greatest concern right now is the availability of new antibiotics to combat diseases as they appear or develop increased resistance to existing treatments. Additionally, we would also benefi t from more treatments for SARS, infl uenza and other viral – as opposed to bacterial – diseases. What is your view on the new class of antibiotics known as “ketolides”? Any new class of antibiotics that helps solve the problem of resistance is welcome. The good safety profi le and oral delivery of these drugs make them especially practical, which would not be the case if we had to inject them or if they had bad side-effects. How would you assess the chances of therapeutic progress in this fi eld? The rate at which bacteria will develop resistance to antibiotics will increase. But the pipeline is drying up because pharmaceutical companies are not developing as many new antibiotics as previously. Existing drugs like Ketek, for example, are very effective in the fi ght against bugs, but new, useful treatments are becoming increasingly scarce. Looking ahead, pharmaceutical companies are likely to focus on developing anti-infectives for illnesses such as Hepatitis and HIV. Drugs for these diseases are potentially more profi table because patients take them over the course of many years, whereas minor infections can generally be cured within a week of antibiotic treatment. It’s hard to persuade drug companies to develop antibiotics. The mechanisms we have in place to guarantee the safety of drugs are arduous and expensive; it currently costs $ 800 million to get a drug to the market. With that level of investment, developing a cholesterol-lowering drug seems more attractive than working on an antibiotic for sinusitis. >> 39
Other <strong>Aventis</strong> Strategic Brands Apart from our leading brands for the therapeutic areas of diabetes, oncology, cardiovascular diseases, respiratory/allergies and human vaccines, we Actonel (risedronate) is a third-generation bisphosphonate that prevents bone loss by inhibiting bone resorption. Approved indications - Treatment and prevention of postmenopausal osteoporosis (PMO) and glucocorticoid-induced osteoporosis - Treatment of Paget’s disease Major markets Actonel is co-marketed by Procter & Gamble Pharmaceuticals and <strong>Aventis</strong> in Europe, the U.S. and Canada through the Alliance for Better Bone Health. In Japan, we market Actonel under a license from Ajinimoto. We market Actonel in other parts of the world under a license agreement with Procter & Gamble Pharmaceuticals. Actonel once- a-day (5 mg) is currently approved in 82 countries and the new once-weekly formulation (35 mg) has been approved in 68 countries. Product features - The only bisphosphonate to offer rapid and sustained vertebral and non-vertebral fracture protection - Helps preserve bone microarchitecture - Excellent gastrointestinal tolerability - Available in 5 mg daily and 35 mg weekly dosage forms >> 40
Page 1 and 2: Life can’t wait. Aventis 2003 Ann
Page 3 and 4: Financial Highlights Net Sales (in
Page 5 and 6: Therapeutic Area Key Developments R
Page 7 and 8: Letter to Shareholders Dear Shareho
Page 9 and 10: Meeting Future Challenges >> 4
Page 11 and 12: Report of the Supervisory Board Dea
Page 13 and 14: 8
Page 16 and 17: 11
Page 18 and 19: Aventis Strategic Brands Taxotere (
Page 20: Expert Opinion on Oncology >> 15
Page 23 and 24: Medical Background Diabetes mellitu
Page 25 and 26: Production and Manufacturing Meetin
Page 28 and 29: 23
Page 30 and 31: Aventis Human Vaccines Pediatric co
Page 32: Expert Opinion on Immunization >> 2
Page 35 and 36: Medical Background Deep vein thromb
Page 37 and 38: Sales and Marketing The Power of Ev
Page 40 and 41: 35
Page 42 and 43: Aventis Strategic Brands Allegra /
Page 46 and 47: Targocid (teicoplanin) is a consist
Page 48 and 49: Key Regulatory Achievements in 2003
Page 50 and 51: program is designed to enable Avent
Page 52 and 53: Africa, we supplied 60 000 vials of
Page 54 and 55: Nutrition and Aventis CropScience i
Page 56 and 57: 51
Page 58 and 59: still constitute a signifi cant par
Page 60 and 61: Your Contacts Your Contacts at Aven
Page 62 and 63: Brand names appearing in italics th

Annual Report 2003 Aventis - Sanofi

Create successful ePaper yourself

Delete template?

Save as template?